摘要:
This invention relates to new RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; to pharmaceutical compositions containing them, and to methods for their use as therapeutic agents.
摘要:
This invention provides the use of RARη selective agonists for the manufacture of a medicament containing one or more such agonists for the treatment of emphysema and other diseases associated with alveolar damage. In another aspect, this invention provides the use of RAR agonists, preferably a RARη selective agonist for the manufacture of medicaments for promoting tropoelastin gene expression and alveolar matrix repair.
摘要:
The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
摘要:
Compounds of formula (I) wherein R?1-R7, R10¿, X and the dotted bond have the meaning given in the specification, bind selectively to retinoid RXR receptors and are useful as antiproliferative agents for dermatological and oncological indications.
摘要:
The current invention provides novel heterocyclic retinoid compounds of formula (I), wherein R1 to R5, A,B,Z and n are as defined in the description and claims. The compounds of the present invention are useful for the treatment and/or prevention of diseases such as chronic obstructive pulmonary disease, cancer and dermatological disorders.
摘要:
New RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification, and pharmaceutically active salts of carboxylic acids of formula (I), further the invention relates to the use of such retinoic acid receptor agonists, particularly retinoic acid receptor η(RARη) selective agonists for the treatment of emphysema and associated pulmonary diseases, as well as for the therapy and prophylaxis of dermatological disorders, for the therapy and prophylaxis of malignant and premalignant epithelial lesions, tumours and precancerous changes of the mucous membrane in the mouth, tongue, larynx, oesophagus, bladder, cervix and colon.
摘要:
Retinoids with retinoid receptor antagonistic activity called retinoid antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found to be efficacious in the treatment of T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.
摘要:
The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
摘要:
New RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification, and pharmaceutically active salts of carboxylic acids of formula (I), further the invention relates to the use of such retinoic acid receptor agonists, particularly retinoic acid receptor η(RARη) selective agonists for the treatment of emphysema and associated pulmonary diseases, as well as for the therapy and prophylaxis of dermatological disorders, for the therapy and prophylaxis of malignant and premalignant epithelial lesions, tumours and precancerous changes of the mucous membrane in the mouth, tongue, larynx, oesophagus, bladder, cervix and colon.
摘要:
Disclosed are compounds of formula (I) in which R1 stands for hydrogen or C¿1-6?-alkyl, R?2¿ stands for C¿1-6?-alkyl or adamantyl, R?3¿ stands for C¿1-6?-alkyl or hydroxy or R?2 and R3¿ together represent -(CR6R7)n-, R4 stands for C¿2-8?-alkyl, C2-8-alkenyl, C2-8-alkinyl, -OCH2R?5¿ or C¿2-8?-alkanoyl and, if R?3¿ is hydroxy, hydrogen, R5 stands for C¿1-6?-alkyl, C2-6-alkenyl or C2-6-alkinyl, R?6 and R7¿ independently of one another represent hydrogen or C¿1-6?-alkyl, Y represents oxygen or sulphur, and n is 3, 4 or 5. These compounds and pharmaceutically usable salts of carboxylic acids of formula (I) act as selective ligands of the retinoic acid η receptor and can be used for treating of epithelial lesions.